Callan JMB Common Stock Performance
| CJMB Stock | 2.01 0.07 3.61% |
Callan JMB holds a performance score of 6 on a scale of zero to a hundred. The company owns a Beta (Systematic Risk) of 6.89, which signifies a somewhat significant risk relative to the market. Callan JMB tends to amplify market moves - gaining more in rallies but giving back more during declines. Use Callan JMB Common the relationship between the treynor ratio and expected short fall, to analyze future returns on Callan JMB Common.
Risk-Adjusted Performance
Contained
Weak | Strong |
Compared with the broader market, risk-adjusted returns on Callan JMB Common rank lower than 6% of all global equities and portfolios over the last 90 days. This score becomes more useful when investors compare it with downside risk, Sharpe Ratio, and current trend stability. Despite somewhat unsteady primary indicators, Callan JMB sustained solid returns over the last few months and may actually be approaching a breakup point. Learn More
1 | Acquisition by Dial Gerald of 461 shares of Callan JMB at 1.22 subject to Rule 16 b-3 | 12/30/2025 |
2 | Callan JMB director Dial buys shares worth 2409 - Investing.com | 01/06/2026 |
3 | Callan JMB Inc. Sees Significant Decrease in Short Interest | 01/13/2026 |
4 | Why Pain Reform Shares Are Trading Higher By 27 Here Are 20 Stocks Moving Premarket - Benzinga | 01/16/2026 |
5 | Acquisition by Duke Liberty Smith of 900 shares of Callan JMB at 1.56 subject to Rule 16 b-3 | 01/28/2026 |
6 | 12 Industrials Stocks Moving In Mondays Intraday Session - Benzinga | 02/02/2026 |
7 | Callan JMB Announces Participation in the i Access Alpha Virtual Best Ideas Spring Investment Conference on March 1011, 2026 | 02/27/2026 |
8 | Callan JMB CEO, Wayne Williams Invited to Attend the 50 th International GMP Conference on March 2-5, 2026 | 03/02/2026 |
9 | Acquisition by Croyle David J of 14805 shares of Callan JMB at 1.762 subject to Rule 16 b-3 | 03/06/2026 |
10 | Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotechs IND Clinical Trials for lodonal in the Treatment of Long COVID | 03/11/2026 |
| Begin Period Cash Flow | 5.2 M | |
| Total Cashflows From Investing Activities | -46.2 K |
Relative Risk vs. Return Landscape
If you had invested $ 173.00 in Callan JMB Common on December 17, 2025 and sold it today you would have earned a total of $ 8.00 from holding Callan JMB Common or generated 4.62% return on investment over 90 days. Callan JMB Common is currently generating a 2.7544% daily expected return and carries 36.309% risk (volatility on return distribution) over a 90-day horizon. In different words, most equities are less risky than Callan, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
Prices of stocks like Callan Stock tend to oscillate around a central value over time, a phenomenon known as mean reversion. Although this tendency is a useful forecasting input, some instruments remain persistently underpriced or overpriced before the market corrects the discrepancy.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 2.01 | 90 days | 2.01 | about 33.85 |
Under a normal probability framework, the likelihood of Callan JMB moving above the current price in 90 days from now is about 33.85 (The distribution above models the probability of Callan Stock reaching different price points within 90 days).
Callan JMB Price Density |
| Price |
Predictive Modules for Callan JMB
The challenge of forecasting Callan JMB Common mirrors the broader difficulty of predicting stock market movements. No single technique offers reliable accuracy, but investors who apply multiple methods and compare the results are better positioned to identify potential outcomes and manage risk effectively.While mean reversion in Callan JMB is a statistically observable tendency, it operates on uncertain timelines. Positions sized too aggressively against the trend can suffer sustained losses before reversion occurs.
Primary Risk Indicators
The stock market has been marked by significant volatility in the last 10-20 years, and Callan JMB has not been spared. Both sharp declines and strong rallies have tested investor discipline. A hedging strategy built around Callan JMB's risk indicators can help those holding Callan JMB Common manage downside risk more effectively.α | Alpha over Dow Jones | 2.81 | |
β | Beta against Dow Jones | 6.89 | |
σ | Overall volatility | 0.60 | |
Ir | Information ratio | 0.08 |
Investor Alerts and Insights
Investors who use alerts for Callan JMB can respond more quickly to important stock events. Notifications for Callan JMB Common highlight significant technical and fundamental shifts that may create new opportunities or signal emerging risks.| Callan JMB Common is way too risky over 90 days horizon | |
| Callan JMB Common appears to be risky and price may revert if volatility continues | |
| The company reported previous year's revenue of 6.56 M. Net Loss for the year was -2.29 M with profit before overhead, payroll, taxes, and interest of 2.17 M. | |
| About 69.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotechs IND Clinical Trials for lodonal in the Treatment of Long COVID |
Price Density Drivers
Callan JMB price dynamics are shaped by the balance between buyer and seller activity. When short interest rises or long traders begin reducing positions, volatility tends to increase. Key market indicators are shown below.
| Common Stock Shares Outstanding | 2.6 M | |
| Cash And Short Term Investments | 2.1 M |
Callan JMB Fundamentals Growth
Investor sentiment toward Callan Stock is largely driven by Callan JMB's fundamental metrics. Revenue growth rates, earnings per share trends, profit margin changes, and leverage ratios are among the most impactful factors determining Callan Stock market behavior.
| Return On Equity | -1.55 | |||
| Return On Asset | -0.51 | |||
| Profit Margin | -1.13 % | |||
| Operating Margin | -1.30 % | |||
| Current Valuation | 7.83 M | |||
| Shares Outstanding | 4.48 M | |||
| Price To Book | 2.04 X | |||
| Price To Sales | 1.37 X | |||
| Revenue | 6.56 M | |||
| Gross Profit | 2.17 M | |||
| EBITDA | -2.12 M | |||
| Net Income | -2.29 M | |||
| Total Debt | 907.45 K | |||
| Book Value Per Share | 0.90 X | |||
| Cash Flow From Operations | 540.35 K | |||
| Earnings Per Share | -1.56 X | |||
| Market Capitalization | 8.11 M | |||
| Total Asset | 5.08 M | |||
| Retained Earnings | -2.29 M | |||
| Working Capital | 2.04 M | |||
Performance Metrics & Calculation Methodology
Callan JMB performance is measured on a risk-adjusted basis against benchmarks. Benchmark comparison clarifies whether outcomes reflect exposure or implementation effects. Callan JMB shows ROE of -1.55%, ROA of -51.33%.
Data shown for Callan JMB Common is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Source publication cadence can introduce delays. Return and risk statistics are calculated from historical price series.